Countries across the globe shut their borders to Britain on Dec. 21 due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages days before Britain is set to leave the European Union.
Final results from Pfizer Inc.’s Covid-19 vaccine trial showed the company’s shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days.
Pfizer Inc.’s experimental Covid-19 vaccine was more than 90% effective based on initial trial results, the company said, a major victory in the fight against a pandemic that has killed more than 1 million people and battered the world’s economy.
Through a definitive merger agreement, BridgeBio acquired 36.3 percent of Eidos Therapeutics’ outstanding common stock that it did not already own.
In an effort to raise up to $400 million, Vesper Healthcare Acquisition Corporation set a $10.00 per-unit price of the company’s initial public offering (IPO) of 40 million units
Covid-19 put many businesses on hold, but not biotech. This sector is growing at record speeds, and only a small portion of the capital deals are related to the pandemic.
Record-breaking coronavirus cases and deaths in several U.S. states are dimming hopes of economic recovery, with cellphone data showing shoppers are staying away from stores in areas where cases are rising the most.
Global coronavirus cases surpassed 5 million, with Latin America overtaking the United States and Europe in the past week to report the largest portion of new daily cases globally.
Shares of New York-based Stemline Therapeutics skyrocketed more than 153 percent in trading after Italy’s Menarini Group announced a $667 million acquisition of the oncology-focused company.
First-quarter 2020 earnings reports are coming out, the stock market remains volatile and much of the world is still on lockdown. In this challenging environment, there are business opportunities abound, “but investors are taking a hard look at their checkbooks,” Keith Bliss, managing partner and CEO of iQ Capital, told BioSpace.